Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lung Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm
Lung Neoplasm

Cancer Family

Lung Neoplasm

CI-CAN-00000221Explore in graph →

Non-malignant2,726 active trials51 approved drugs619 evidence items

NCIt: C3200
MeSH: D008175

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11603
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
· Lancet Oncol · 2018 · PMID 30413378 · validated civic_curation pubmed
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
· Ann Oncol · 2019 · PMID 31086949 · validated civic_curation pubmed
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
· N Engl J Med · 2020 · PMID 32846060 · validated civic_curation pubmed
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
· N Engl J Med · 2023 · PMID 37611121 · validated civic_curation pubmed
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
· Science · 2015 · PMID 25765070 · validated civic_curation pubmed
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
· JAMA Oncol · 2022 · PMID 35708671 · validated civic_curation pubmed
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
· Nat Med · 2018 · PMID 30082870 · validated civic_curation

Showing 201–225 of 483 publications

← Previous
1
…
8
9
10
…
20
Next →

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

· N Engl J Med · 2018 · PMID 29658845 · validated civic_curation pubmed

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.

· JAMA Oncol · 2019 · PMID 30816954 · validated civic_curation pubmed

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2025 · PMID 41100773 · validated civic_curation pubmed

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.

· Cancer Cell · 2024 · PMID 39255777 · validated civic_curation pubmed

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

· Mol Cancer · 2022 · PMID 34980131 · validated civic_curation pubmed

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

· Cancer Cell · 2018 · PMID 29657128 · validated cbioportal_study pubmed

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

· PLoS Med · 2005 · PMID 15696205 · validated civic_curation pubmed

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

· Clin Cancer Res · 2008 · PMID 18794081 · validated civic_curation pubmed

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

· Clin Cancer Res · 2012 · PMID 23014527 · validated civic_curation pubmed

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

· J Thorac Oncol · 2014 · PMID 24736073 · validated civic_curation pubmed

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

· N Engl J Med · 2005 · PMID 15728811 · validated civic_curation pubmed

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

· Neoplasia · 2009 · PMID 19794967 · validated civic_curation pubmed

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

· J Clin Oncol · 2001 · PMID 11208838 · validated civic_curation pubmed

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.

· Lung Cancer · 2007 · PMID 17070615 · validated civic_curation pubmed

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.

· J Thorac Oncol · 2014 · PMID 24662454 · validated civic_curation pubmed

CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.

· Diagn Mol Pathol · 2012 · PMID 23111194 · validated civic_curation pubmed

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

· Br J Cancer · 2005 · PMID 15597105 · validated civic_curation pubmed

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.

· J Cell Mol Med · 2009 · PMID 19040416 · validated civic_curation pubmed